首页> 外文期刊>Progres en urologie: journal de l’Association francaise d’urologie et de la Societefrancaise d’urologie >Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma [Valeur pronostique de la toxicité induite par les thérapies ciblées dans le carcinome rénal métastatique]
【24h】

Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma [Valeur pronostique de la toxicité induite par les thérapies ciblées dans le carcinome rénal métastatique]

机译:靶向治疗所致毒性转移对转移性肾细胞癌患者的预后价值[靶向治疗所致毒性转移对转移性肾细胞癌的预后价值]

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To assess the prognostic value of clinical and biological variables in the era of targeted therapies, especially induced toxicity in patients treated for metastatic renal cell carcinoma (RCC). Patients and methods: A retrospective single-center study was performed in patients treated in our center from 2006to 2012. The clinical and biological variables and toxicity data were retrospectively collected. Survival rates were calculated using the Kaplan-Meier method and compared by the Log-Rank test. Multivariate analysis was also performed using the Cox model. Results: One hundred and two patients were included, with a median follow-up of 20. months. The median overall survival (OS) was 21. months, and 6. months for the progression free survival (PFS). As expected, the variables included in the Mozter prognostic score had a significant impact on OS (P< 0.0001) and PFS (P< 0.0001). However, hypoalbuminemia (P< 0.0001), brain metastasis (P= 0.003) and the absence of nephrectomy (P< 0.0001) were found as poor prognosis factors for OS. In addition, severe toxicity (grade 3-4) was significantly associated with higher OS (P< 0.0001) and PFS (P= 0.0003) and appeared as an independent factor in multivariate analysis for OS (P= 0.02) and PFS (P= 0.01). Conclusion: Severe toxicity induced by targeted therapies was found as a prognostic factor increasing significantly the survival. Further studies are needed to assess the real value of this factor in the development of sequential therapies for the treatment of RCC.
机译:目的:评估靶向治疗时代的临床和生物学变量的预后价值,尤其是转移性肾细胞癌(RCC)患者的诱发毒性。患者和方法:对2006年至2012年在我们中心接受治疗的患者进行回顾性单中心研究。回顾性收集临床和生物学变量以及毒性数据。使用Kaplan-Meier方法计算存活率,并通过Log-Rank检验进行比较。还使用Cox模型进行了多变量分析。结果:纳入102例患者,中位随访20个月。中位总生存期(OS)为21.个月,无进展生存期(PFS)为6.个月。正如预期的那样,莫兹特病预后评分中包含的变量对OS(P <0.0001)和PFS(P <0.0001)有显着影响。然而,发现低白蛋白血症(P <0.0001),脑转移(P = 0.003)和不进行肾切除术(P <0.0001)是OS的不良预后因素。此外,严重毒性(3-4级)与较高的OS(P <0.0001)和PFS(P = 0.0003)显着相关,并且在OS(P = 0.02)和PFS(P = 0.01)。结论:靶向治疗引起的严重毒性被认为是预后显着增加生存率的因素。需要进一步的研究来评估该因素在开发用于RCC的序贯疗法中的真正价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号